Bobigny Cedex

• CBD-OH - Cannabidiol as an add-on treatment during inpatient alcohol cessation in patients with severe alcohol use disorder: a Phase II tria … Recruiting
  2024-518455-28-00 4 2024-07-03 Patients with severe Alcohol Use Disorder (according to DSM 5) at entr
• Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy : A randomized phase III trial - COnCERTO (French 01-18) 20 … Recruiting
  2024-516456-17-00 5 2024-05-07 patients admitted for an obstructive colon cancer
• Amoxicillin alone versus amoxicillin/clavulanate for community-acquired pneumonia in patients aged 65 years or older, and hospitalized in a … Recruiting
  2023-503645-63-00 5 2024-04-25 Patients aged 65 years or older, hospitalized in a non-ICU ward for a
• DUMELEP trial - Durvalumab (MEDI4736)/Tremelimumab in neoadjuvant and adjuvant setting in patients with HCC treated by percutaneous ablation … Recruiting
  2024-515768-30-01 4 2024-03-28 Hepatocellular carcinoma
• A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting
  2022-502741-10-00 7 2024-01-26 Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearrangement or Nucl
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• EvER-ILD 2: Evaluation of Efficacy and safety of Rituximab in patients with progressive Interstitial Lung Disease (ILD) with inflammatory co … Recruiting
  2022-501335-16-00 10 2023-01-16 Interstitial lung disease
• ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care Recruiting
  2024-513327-16-00 5 2022-09-20 Intensive care
• CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting
  2022-500295-60-00 4 2022-09-15 Acute Myeloid Leukemia
• VAC-WARTS Recruiting
  2024-513671-40-00 5 2022-06-29 HPV vaccine
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl … Recruiting
  2023-506891-28-00 5 2022-05-02 The target population of interest in this study is participants with l
• CHOLINE-2 - Donepezil Versus Non-drug Treatment in Alzheimer's Disease Recruiting
  2024-515038-34-00 6 2022-02-10 Interest of adding donepezil to the non-medicinal care pathway recomme
• IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre … Recruiting
  2024-517215-67-00 5 2021-06-11 Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
• LOADEX: PILOT AND PHASE 2 STUDY OF THE EFFICACY OF A TREATMENT PROTOCOL WITH DEXAMETHASONE IMPLANT LOADING DOSE IN PATIENTS WITH DIABETIC MA … Recruiting
  2024-514362-39-00 4 2019-12-05 Diabetic macular oedema
• CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co … Recruiting
  2024-518578-15-00 5 2018-02-05 Is to demonstrate a non inferior efficacy of azithromycin and so the p
• Evaluation of the efficacy and safety of drug treatment in familial polycythemia associated with an EPO gene mutation: a multicentre, open-l … Ended recruitment
  2025-521906-16-00 3 2025-08-01 familial polycythemia associated with an EPO gene mutation
• Evaluation of TNF-alpha antagonists (infliximab) withdrawal in sarcoidosis Ended recruitment
  2024-516965-35-00 5 2024-10-28 Immune system disorders
• Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) Ended recruitment
  2023-507891-31-00 10 2024-10-11 Human Immunodeficiency Virus (HIV-1) infection
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co … Ended recruitment
  2022-502161-19-00 5 2024-03-12 Chronic Spontaneous Urticaria
• Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran … Ended recruitment
  2024-514876-41-00 9 2023-12-06 Higher-risk myelodysplastic syndromes untreated and ineligible for all
• SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma Ended recruitment
  2022-502012-37-00 5 2023-10-06 Advanced Hepatocellular Carcinoma
• Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended recruitment
  2024-514878-53-00 4 2023-10-04 HMA-naïve, higher-risk (HR, defined as CPSS-mol risk intermediate-2 or
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma

Showing 49–72 of 112 trials